"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02068820","Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG",,"Completed","Has Results","Endometrial Cancer","Device: ISB dye and standard white light imaging|Device: ICG dye and FireFly fluorescence imaging","Number of Pelvic Sentinel Lymph Nodes (SLN) in Endometrial Cancer Patients Detected by Either ICG and/or ISB Dyes.|Negative Predictive Value (NPV) of Pelvic SLN in Endometrial Cancer in Relation to the Number of Nodes With Metastasis.","AdventHealth","Female","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SLN Mapping","September 2012","January 2015","January 2015","February 21, 2014","September 10, 2019","September 10, 2019","Florida Hospital Gynecologic Oncology, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02068820"
2,"NCT01673022","Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging","FIRES","Completed","Has Results","Endometrial Cancer|Cervical Cancer","Drug: IC Green","Estimate the Sensitivity of the Sentinel Lymph Node","Indiana University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","430","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1204008493","May 2012","January 2017","January 2017","August 27, 2012","July 24, 2018","July 24, 2018","USA Mitchell Cancer Institute, Mobile, Alabama, United States|Indiana University, Indianapolis, Indiana, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Tri Health Good Smaritan Hospital, Cincinnati, Ohio, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01673022"
3,"NCT02279108","Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer","FLUOTECH","Completed","Has Results","Breast Neoplasms","Drug: indocyanine green|Drug: isotope","Number of Patients With Less Than Two Lymph Nodes Detected|Number of Lymph Nodes ICG Positive and Tc Positive|Number of Lymph Nodes ICG Positive and Tc Negative|Number of Lymph Nodes ICG Negative and Tc Positive|Comparison Between Groups of the Time of the Surgery|Comparison Between Groups of Anesthesia Time|Time From Injection of One Dose ICG Injection to Incision Time|Comparison Between Groups of Time Surgery Node|Number of Patients With ICG Allergy","Centre Hospitalier Universitaire de Saint Etienne","Female","18 Years and older   (Adult, Older Adult)","Phase 3","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1408153|2014-004005-32","November 2014","May 2016","July 2016","October 30, 2014","April 9, 2018","April 9, 2018","Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France",,"https://ClinicalTrials.gov/show/NCT02279108"
4,"NCT01818739","Lymph Node Mapping in Patients With Endometrial Cancer",,"Completed","Has Results","Endometrial Cancer","Procedure: sentinel lymph node detection|Drug: indocyanine green solution|Drug: isosulfan blue|Procedure: sentinel lymph node biopsy","Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease|Percentage of Metastatic Cases Found Using Ultra-sectioning and IHC Staining","Ohio State University Comprehensive Cancer Center","Female","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","204","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OSU-12114|NCI-2013-00530","March 2013","November 16, 2016","March 31, 2017","March 26, 2013","June 22, 2021","June 22, 2021","Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01818739"
5,"NCT02946021","Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema",,"Completed","Has Results","Head and Neck Neoplasms|Head and Neck Lymphedema|Head and Neck Cancer","Device: Head and neck garments for pneumatic compression device|Drug: NIRFLI with ICG","Lymph Movement Measured by ICG Lymphography.|Dermal Backflow Measured by ICG Lymphography.|Symptom Alleviation Measured by Survey Response.|Ease of Use Measured by Survey Response.","Tactile Medical","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-16-0465","October 2016","February 2018","February 2018","October 26, 2016","March 20, 2019","April 9, 2019","UT Health Science Center at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02946021/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02946021"
6,"NCT02209532","A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping","FILM","Completed","Has Results","Endometrial Cancer|Uterine Cancer|Cervical Cancer","Device: PINPOINT","Effectiveness of PINPOINT and IC2000 in the Identification of Lymph Nodes Defined as the Proportion of Confirmed Lymph Nodes Identified|Effectiveness of PINPOINT and Blue Dye in the Identification of at Least One Lymph Node Defined as the Number of Subjects in Which at Least One Confirmed Lymph Node Was Identified With Either PINPOINT or Blue Dye|Effectiveness of PINPOINT and Blue Dye in the Identification of Bilateral Lymph Nodes Defined as the Number of Subjects in Which Lymph Nodes Were Identified Bilaterally With Either PINPOINT or Blue Dye.|Identification of Lymph Nodes Following Lymphatic Channels Defined as the Number of Subjects in Which Confirmed Lymph Nodes Were Identified by Following a Lymphatic Channel With Either PINPOINT or Blue Dye.|Safety of Interstitial Injection of ICG Defined as the Number of Adverse Effects Related to ICG|Anatomic Distribution of Lymph Nodes","Novadaq Technologies ULC, now a part of Stryker","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PP LNM 01","December 2015","June 2017","June 2017","August 6, 2014","March 25, 2019","March 25, 2019","O'Connor Hospital, San Jose, California, United States|Lee Memorial Hospital, Fort Myers, Florida, United States|Memorial Sloan Kettering, New York, New York, United States|Duke Cancer Institute, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|CHU de Québec - Université Laval, Quebec City, Quebec, Canada|Hospital HIMA San Pablo, Caguas, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02209532/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02209532/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02209532"
7,"NCT02419807","Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer",,"Completed","Has Results","Stage I Breast Cancer|Stage II Breast Cancer","Drug: Indocyanine Green Solution|Radiation: Technetium Tc-99m Sulfur Colloid|Procedure: Lymphoscintigraphy|Procedure: Axillary Lymph Node Biopsy","Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods","Case Comprehensive Cancer Center|National Cancer Institute (NCI)|Mitaka USA, Inc.","Female","Child, Adult, Older Adult","Not Applicable","102","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CASE10114","February 17, 2015","February 2019","February 2019","April 17, 2015","October 22, 2020","November 16, 2020","Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02419807/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02419807/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02419807"
8,"NCT03072186","Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery","ICG2","Completed","Has Results","Skull Base Neoplasms|Skull Neoplasms|Bone Neoplasm|Neoplasms|Bone Diseases|Musculoskeletal Disease","Device: near-infrared light nasal endoscope used with ICG","ICG Fluorescence Ratio","Ohio State University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","23","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016H0193","November 6, 2017","January 15, 2019","January 24, 2019","March 7, 2017","March 8, 2021","April 26, 2021","The Ohio State University, Columbus, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03072186/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03072186"
